Literature DB >> 2910827

Effects of activators of protein kinase C, including bryostatins 1 and 2, on the growth of A549 human lung carcinoma cells.

I L Dale1, A Gescher.   

Abstract

Phorbol esters such as 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibit the growth of A549 human lung carcinoma cells at non-toxic concentrations, whereas 1-oleoyl-2-acetylglycerol and 1,2-dioctanoylglycerol, synthetic analogues of the physiological ligands of protein kinase C (PKC), do not. Experiments were conducted to test the hypothesis that other activators of PKC are capable of interfering with A549 cell growth. The non-phorboid tumour promotor mezerein mimicked the growth-inhibitory effect of TPA in that it arrested growth for 5 days, after which cells proliferated again in the continued presence of the agent. TPA was 20 times more potent as a growth inhibitor than was mezerein. Bryostatin 1 at 10 nM and bryostatin 2 at 100 nM also arrested A549 cell growth and inhibited DNA replication as measured by incorporation of [methyl-3H]-thymidine into cells. Inhibition of DNA synthesis to between 90 and 75% of control values developed during the first hour of incubation of the cells with TPA, mezerein or the bryostatins. The extent of inhibition changed little during the subsequent 5 hr of incubation, after which it increased further to reach maximal values within 12 hr. At concentrations above those which caused maximal growth inhibition, the bryostatins abolished both their own inhibition of DNA synthesis and the anti-replicative effect of TPA and mezerein. The results show that activators of PKC other than phorbol esters are capable of inhibiting the growth of A549 cells. The bryostatins not only interfere with A549 cell growth but can also counter the growth-inhibitory effect of PKC activators, presumably via interaction with a target separate from the phorbol ester receptor site.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2910827     DOI: 10.1002/ijc.2910430129

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  19 in total

1.  Effect of intravenous infusions of 12-O-tetradecanoylphorbol-13-acetate (TPA) in patients with myelocytic leukemia: preliminary studies on therapeutic efficacy and toxicity.

Authors:  Z T Han; X X Zhu; R Y Yang; J Z Sun; G F Tian; X J Liu; G S Cao; H L Newmark; A H Conney; R L Chang
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-28       Impact factor: 11.205

Review 2.  Protein kinase C targeting in antineoplastic treatment strategies.

Authors:  W D Jarvis; S Grant
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

3.  Phase II trial of bryostatin-1 in combination with cisplatin in patients with recurrent or persistent epithelial ovarian cancer: a California cancer consortium study.

Authors:  Robert J Morgan; Lucille Leong; Warren Chow; David Gandara; Paul Frankel; Agustin Garcia; Heinz-Josef Lenz; James H Doroshow
Journal:  Invest New Drugs       Date:  2010-10-09       Impact factor: 3.850

4.  Different biological effects of the two protein kinase C activators bryostatin-1 and TPA on human carcinoma cell lines.

Authors:  K G Steube; D Grunicke; H G Drexler
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

5.  A cell-based reporter assay for the identification of protein kinase C activators and inhibitors.

Authors:  P Sista; S Edmiston; J W Darges; S Robinson; D J Burns
Journal:  Mol Cell Biochem       Date:  1994-12-21       Impact factor: 3.396

Review 6.  Signaling inhibitors in the treatment of prostate cancer.

Authors:  Gary R Hudes
Journal:  Invest New Drugs       Date:  2002-05       Impact factor: 3.850

7.  A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma.

Authors:  Amy C Peterson; Helena Harlin; Theodore Karrison; Nicholas J Vogelzang; James A Knost; John W Kugler; Eric Lester; Everett Vokes; Thomas F Gajewski; Walter M Stadler
Journal:  Invest New Drugs       Date:  2006-03       Impact factor: 3.850

8.  Phorbol esters induce death in MCF-7 breast cancer cells with altered expression of protein kinase C isoforms. Role for p53-independent induction of gadd-45 in initiating death.

Authors:  J E de Vente; C A Kukoly; W O Bryant; K J Posekany; J Chen; D J Fletcher; P J Parker; G J Pettit; G Lozano; P P Cook
Journal:  J Clin Invest       Date:  1995-10       Impact factor: 14.808

Review 9.  Protein Kinase C as a Therapeutic Target in Non-Small Cell Lung Cancer.

Authors:  Mohammad Mojtaba Sadeghi; Mohamed F Salama; Yusuf A Hannun
Journal:  Int J Mol Sci       Date:  2021-05-24       Impact factor: 5.923

10.  12-O-tetradecanoylphorbol 13-acetate induced differentiation in human lung squamous carcinoma cells.

Authors:  G J Rabiasz; S P Langdon; L Anderson; A A Ritchie; W R Miller; J F Smyth
Journal:  Br J Cancer       Date:  1992-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.